Klingenstein Fields & CO LP Regeneron Pharmaceuticals, Inc. Transaction History
Klingenstein Fields & CO LP
- $2.49 Billion
- Q2 2025
A detailed history of Klingenstein Fields & CO LP transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Klingenstein Fields & CO LP holds 16,099 shares of REGN stock, worth $8.94 Million. This represents 0.34% of its overall portfolio holdings.
Number of Shares
16,099
Previous 6,944
131.84%
Holding current value
$8.94 Million
Previous $4.4 Million
91.89%
% of portfolio
0.34%
Previous 0.19%
Shares
9 transactions
Others Institutions Holding REGN
# of Institutions
1,431Shares Held
84.9MCall Options Held
1.39MPut Options Held
1.42M-
Vanguard Group Inc Valley Forge, PA9.41MShares$5.22 Billion0.11% of portfolio
-
Black Rock Inc. New York, NY8.45MShares$4.69 Billion0.2% of portfolio
-
Jpmorgan Chase & CO New York, NY5.66MShares$3.14 Billion0.28% of portfolio
-
State Street Corp Boston, MA4.79MShares$2.66 Billion0.13% of portfolio
-
Capital International Investors Los Angeles, CA3.99MShares$2.21 Billion0.52% of portfolio
About REGENERON PHARMACEUTICALS, INC.
- Ticker REGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 107,190,000
- Market Cap $59.5B
- Description
- Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...